All In Biotech

Drug Trial Radar · NCT04314986

Multiple Ascending Dose Study of AR882 in Healthy Adult Male Volunteers

A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study of AR882, a Potent Uricosuric Agent, in Healthy Adult Male Volunteers

Last checked: Nov 19, 2026Latest source record: Nov 16, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

30

Actual

Start

Jun 28, 2019

Primary completion

Sep 18, 2019

Study completion Sep 18, 2019

Sponsor

Lead sponsor
Arthrosi TherapeuticsIndustry
Sponsor type
Industry
First posted
Mar 19, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

A study to assess multiple ascending doses of AR882 in healthy adult males.

Conditions

  • Healthy Volunteers

Interventions

  • Cohort 1: AR882 or placeboDrug

    AR882 or matching placebo administered once daily for 10 days

  • Cohort 2: AR882 or placeboDrug

    AR882 or matching placebo administered once daily for 10 days.

  • Cohort 3: AR882 or placeboDrug

    AR882 or matching placebo administered once daily for 10 days

  • Cohort 4: AR882 or placeboDrug

    AR882 or matching placebo administered once daily for 10 days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To evaluate the safety profile of AR882 based on incidence of adverse eventsTime frame: 22 Days
  2. To evaluate the safety profile of AR882 based on incidence of abnormal laboratory findingsTime frame: 22 Days
  3. To evaluate the safety profile of AR882 based on incidence of abnormal electrocardiogram findingsTime frame: 22 Days
  4. To evaluate the safety profile of AR882 based on incidence of abnormal vital signs findingsTime frame: 22 Days
  5. Area under the curve (AUC) for plasma AR882Time frame: 15 Days
  6. Time to maximum plasma concentration (Tmax) for AR882Time frame: 15 Days
  7. Maximum plasma concentration (Cmax) for AR882Time frame: 15 Days
  8. Apparent terminal half-life (t1/2) for AR882Time frame: 15 Days
  9. Amount excreted (Ae) into urine for AR882Time frame: 15 Days
  10. Fractional Excretion (FEUA) for AR882Time frame: 15 Days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Nucleus Network Pty, Ltd.

    Melbourne, Victoria, Australia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.